A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2029-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax
(I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively
reduced or reactively modified in response to adverse events (AEs).